Literature DB >> 12424513

Ibutilide-induced long QT syndrome and torsade de pointes.

Ramesh M Gowda1, Gopikrishna Punukollu, Ijaz A Khan, Raghotham R Patlola, Furqan H Tejani, Braulio F Cosme-Thormann, Balendu C Vasavada, Terrence J Sacchi.   

Abstract

Ibutilide is a class III antiarrhythmic agent used for the termination of atrial fibrillation and atrial flutter. It mainly affects membrane potassium currents and prolongs the cardiac action potential. This effect is reflected as QT interval prolongation on the surface electrocardiogram. Like other drugs that affect potassium currents, ibutilide is prone to induce a malignant ventricular tachycardia, torsade de pointes. We report four cases of torsade de pointes after administration of ibutilide for pharmacologic cardioversion of atrial fibrillation and atrial flutter; three of these cases required direct current cardioversion for termination of torsade de pointes. All four patients were female. We discuss the risk factors for development of ibutilide-induced torsade de pointes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424513     DOI: 10.1097/00045391-200211000-00013

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

1.  ECG Diagnosis: Ibutilide-induced Torsade de Pointes.

Authors:  Daphne D Le; Joel T Levis; Nelya Lugovskaya; David R Vinson
Journal:  Perm J       Date:  2019

Review 2.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

Review 3.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.